Evaluating the potential effect on fetal tissue after exposure to granisetron during pregnancy

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Developmental Toxicology

Background:

• Granisetron is a 5-HT3 receptor antagonist used to prevent nausea and vomiting.
• Assessing fetal tissue toxicity of medications during pregnancy is crucial for maternal and infant safety.

Purpose of the Study:

• To investigate the potential toxic effects of granisetron on human fetal tissues at clinically relevant concentrations.
• To evaluate granisetron's impact on cell cycle progression and apoptosis in primary fetal cells.

Main Methods:

• Primary cells from human fetal organs (16-19 weeks gestation) were exposed to granisetron (3 ng/mL and 30 ng/mL).
• Cell cycle progression was analyzed using flow cytometry.
• Apoptosis was assessed by detecting major apoptotic proteins via ELISA.

Main Results:

• Granisetron at 30 ng/mL induced up to 10% apoptosis in fetal cardiac tissue.
• Neither granisetron concentration affected cell cycle progression in any tested fetal tissue.
• No significant alterations in apoptotic proteins were observed in other fetal tissues.

Conclusions:

• High-dose granisetron (30 ng/mL) may pose a risk of apoptosis in fetal cardiac tissue, requiring further clinical evaluation.
• Low-dose granisetron (3 ng/mL) demonstrated no detectable toxicity in the studied fetal tissues.
• Additional research is necessary to confirm these findings and ascertain clinical significance.